药康生物(688046)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688046 药康生物

已收盘 04-30 15:00:00

{"stockData":{"symbol":"688046","market":"SH","secType":"STK","nameCN":"药康生物","latestPrice":12.72,"timestamp":1714460400000,"preClose":13.04,"halted":0,"volume":4183953,"delay":0,"floatShares":204000000,"shares":409999999,"eps":0.3838,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.32,"latestTime":"04-30 15:00:00","open":13.03,"high":13.03,"low":12.54,"amount":53332500,"amplitude":0.0376,"askPrice":12.72,"askSize":5,"bidPrice":12.7,"bidSize":514,"shortable":0,"etf":0,"ttmEps":0.3838,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714959000000},"adr":0,"adjPreClose":13.04,"symbolType":"stock_kcb","openAndCloseTimeList":[[1714440600000,1714447800000],[1714453200000,1714460400000]],"highLimit":14.34,"lowLimit":11.74,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":410000000,"pbRate":2.45,"roa":"--","roe":"1.39%","epsLYR":0.39,"committee":0.730185,"marketValue":5215000000,"floatMarketCap":2594000000,"peRate":33.142262,"changeRate":-0.0245,"turnoverRate":0.0205,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2024-05-06。","afterMarket":{"amount":0,"volume":0,"close":12.72,"buyVolume":0,"sellVolume":0,"time":1714462439505,"indexStatus":"已收盘 04-30 15:30:00","preClose":13.04}},"requestUrl":"/m/hq/s/688046","defaultTab":"news","newsList":[{"id":"2431366808","title":"药康生物04月30日遭主力抛售239万元 环比增加1891.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431366808","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431366808?lang=zh_cn&edition=full","pubTime":"2024-04-30 15:18","pubTimestamp":1714461492,"startTime":"0","endTime":"0","summary":"04月30日, 药康生物股价跌2.45%，报收12.72元，成交金额5333万元，换手率2.05%，振幅3.76%，量比1.17。药康生物今日主力资金净流出239万元，上一交易日主力净流出12万元，今日环比增加1891.67%。该股近5个交易日上涨7.07%，主力资金累计净流出499万元；近20日主力资金累计净流入394万元，其中净流入天数为11日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301527318b6533c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301527318b6533c5&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431549263","title":"药康生物获开源证券买入评级，海内外产能陆续投产，国际化发展推动收入稳健增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2431549263","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2431549263?lang=zh_cn&edition=full","pubTime":"2024-04-30 14:14","pubTimestamp":1714457678,"startTime":"0","endTime":"0","summary":"4月30日，药康生物获开源证券买入评级，近一个月药康生物获得3份研报关注。研报预计2024-2026年归母净利润为2.04/2.51/3.19亿元。研报认为，公司营收端稳健增长，利润端受持续高强度研发投入、新产能投产后折旧摊销增加等因素影响阶段性承压。公司坚持“产品+服务”双轮驱动的业务模式，持续推进非肿瘤模型以及野化鼠等新领域建设，海外业务快速发展。我们看好公司长期发展，维持2024-2025年盈利预测并新增2026年盈利预测。鉴于公司积极开发高附加值品系且积极拓展海外市场，维持“买入”评级。风险提示：模式动物行业需求下降、核心成员流失、行业竞争格局恶化等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043014144387c2673c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043014144387c2673c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431355471","title":"开源证券：给予药康生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2431355471","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431355471?lang=zh_cn&edition=full","pubTime":"2024-04-30 13:45","pubTimestamp":1714455928,"startTime":"0","endTime":"0","summary":"开源证券股份有限公司余汝意,汪晋近期对药康生物进行研究并发布了研究报告《公司信息更新报告：海内外产能陆续投产，国际化发展推动收入稳健增长》，本报告对药康生物给出买入评级，当前股价为12.84元。最新盈利预测明细如下：该股最近90天内共有7家机构给出评级，买入评级4家，增持评级3家；过去90天内机构目标均价为19.37。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024043000025346.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431433813","title":"药康生物：产能提升助力未来业绩增长，“创新+国际化”战略稳步推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2431433813","media":"证券时报网","top":-1,"share":"https://www.laohu8.com/m/news/2431433813?lang=zh_cn&edition=full","pubTime":"2024-04-30 11:08","pubTimestamp":1714446480,"startTime":"0","endTime":"0","summary":"近年来，药康生物持续强化核心竞争力，产能扩建、新品系研发，以及海外业务的快速增长，都为企业长期业绩增长提供了不少期待。公司表示，药康生物始终围绕创新与国际化两大核心战略，紧跟生命科学发展前沿，持续推出创新模型，满足行业未被满足需求，开拓小鼠模型应用场景，以创新模型提升行业天花板，以创新模型打开国际市场，立足中国，走向世界。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043011084587c1deb9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043011084587c1deb9&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431396094","title":"药康生物(688046)：海外市场营收同比增长40% 国内外新产能陆续投产","url":"https://stock-news.laohu8.com/highlight/detail?id=2431396094","media":"国信证券股份有...","top":-1,"share":"https://www.laohu8.com/m/news/2431396094?lang=zh_cn&edition=full","pubTime":"2024-04-30 00:00","pubTimestamp":1714406400,"startTime":"0","endTime":"0","summary":"海外市场营收同比增长40%，毛利率环比改善。2023 年，公司实现营收6.22亿元，归母净利润1.59 亿元，扣非归母净利润1.07 亿元，预计主要由于公司目前仍处业务扩张期，持续高强度研发投入、加大海外市场开拓力度、生产人员扩招、新产能投产后折旧摊销增加等原因致使公司利润短期承压。国内外新产能陆续投产。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301648148b658182&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301648148b658182&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431882892","title":"4月29日药康生物现347.2万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2431882892","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431882892?lang=zh_cn&edition=full","pubTime":"2024-04-29 17:21","pubTimestamp":1714382462,"startTime":"0","endTime":"0","summary":"证券之星消息，4月29日药康生物发生大宗交易，交易数据如下：大宗交易成交价格12.4元，相对当日收盘价折价4.91%，成交28万股，成交金额347.2万元，买方营业部为海通证券股份有限公司深圳滨河大道证券营业部，卖方营业部为华泰证券股份有限公司杭州解放东路证券营业部。近三个月该股共发生1笔大宗交易，合计成交2800.0手，折价成交1笔。截至2024年4月29日收盘，药康生物报收于13.04元，上涨5.67%，换手率2.48%，成交量5.07万手，成交额6478.47万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291723388b614d9b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291723388b614d9b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431888058","title":"4月29日药康生物涨5.67%，财通优势行业轮动混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2431888058","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431888058?lang=zh_cn&edition=full","pubTime":"2024-04-29 16:28","pubTimestamp":1714379320,"startTime":"0","endTime":"0","summary":"证券之星消息，4月29日药康生物涨5.67%，收盘报13.04元，换手率2.48%，成交量5.07万手，成交额6478.47万元。重仓药康生物的公募基金请见下表：该股最近90天内共有7家机构给出评级，买入评级4家，增持评级3家；过去90天内机构目标均价为19.37。根据2024基金Q1季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为财通优势行业轮动混合A。该公募基金现任基金经理为张胤。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042900017028.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431041984","title":"北向资金4月26日净买入药康生物9.25万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2431041984","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431041984?lang=zh_cn&edition=full","pubTime":"2024-04-29 09:30","pubTimestamp":1714354237,"startTime":"0","endTime":"0","summary":"4月26日, 北向资金增持药康生物9.25万股，连续3日增持。截止当日收盘，沪股通共持有药康生物213.14万股，占流通股1.04%。沪股通增持金额前五个股分别为招商银行、贵州茅台、兴业银行、药明康德、三一重工。药康生物近5个交易日上涨9.88%，沪股通累计增持38.64万股；近20个交易日下跌5.87%，沪股通累计减持1.68万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404290936438b5f9dcd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404290936438b5f9dcd&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430983797","title":"药康生物(688046)3月31日股东户数0.8万户，较上期增加26.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430983797","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430983797?lang=zh_cn&edition=full","pubTime":"2024-04-27 17:09","pubTimestamp":1714208981,"startTime":"0","endTime":"0","summary":"证券之星消息，近日药康生物披露，截至2024年3月31日公司股东户数为8007.0户，较12月31日增加1668.0户，增幅为26.31%。在医疗服务行业个股中，药康生物股东户数低于行业平均水平，截至3月31日，医疗服务行业平均股东户数为4.14万户。从股价来看，2023年12月31日至2024年3月31日，药康生物区间跌幅为36.18%，在此期间股东户数增加1668.0户，增幅为26.31%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042700024732.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430764187","title":"药康生物：2024年第一季度净利润约2948万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430764187","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2430764187?lang=zh_cn&edition=full","pubTime":"2024-04-27 12:09","pubTimestamp":1714190975,"startTime":"0","endTime":"0","summary":"药康生物（SH 688046，收盘价：12.34元）4月27日发布一季度业绩公告称，2024年第一季度营收约1.57亿元，同比增加11.96%；归属于上市公司股东的净利润约2948万元，同比减少5.06%。文章来源：每日经济新闻原标题：药康生物：2024年第一季度净利润约2948万元","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042712292887b6108a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042712292887b6108a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430435227","title":"药康生物(688046.SH)发布一季度业绩，净利润2947.94万元，同比下降5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430435227","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430435227?lang=zh_cn&edition=full","pubTime":"2024-04-26 19:09","pubTimestamp":1714129780,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药康生物(688046.SH)发布2024年第一季度报告，公司营业收入1.57亿元，同比增长11.96%;归属于上市公司股东的净利润2947.94万元，同比下降5.06%;归属于上市公司股东的扣除非经常性损益的净利润2286.81万元，同比增长2.74%;基本每股收益0.07元/股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1112015.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430227874","title":"药康生物(688046.SH)发布2023年度业绩，净利润1.59亿元，同比下降3.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430227874","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430227874?lang=zh_cn&edition=full","pubTime":"2024-04-26 19:06","pubTimestamp":1714129562,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药康生物(688046.SH)发布2023年年度报告，公司营业收入6.22亿元，同比增长20.45%;归属于上市公司股东的净利润1.59亿元，同比下降3.49%;归属于上市公司股东的扣除非经常性损益的净利润1.07亿元，同比增长5.00%;基本每股收益0.39元/股。拟向全体股东每10股派发现金红利1.60元(含税)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1112000.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430241317","title":"药康生物（688046）200万股限售股将于4月25日解禁上市，占总股本0.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430241317","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430241317?lang=zh_cn&edition=full","pubTime":"2024-04-25 08:02","pubTimestamp":1714003348,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，药康生物于4月25日将有200.0万股限售股份解禁上市，为公司首发战略配售股份，占公司总股本0.49%。最近一年内，该股累计解禁5472.0万股，占总股本的13.35%。本次解禁后，公司还有2.06亿股限售股份，占总股本50.26%。药康生物主营业务：实验动物模型的研发创制、生产销售及相关技术服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500013787.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430411955","title":"A股限售股解禁一览：5.38亿元市值限售股今日解禁","url":"https://stock-news.laohu8.com/highlight/detail?id=2430411955","media":"第一财经","top":-1,"share":"https://www.laohu8.com/m/news/2430411955?lang=zh_cn&edition=full","pubTime":"2024-04-25 07:45","pubTimestamp":1714002314,"startTime":"0","endTime":"0","summary":"Wind数据显示，周四，共有3家公司限售股解禁，合计解禁量为1441.36万股，按最新收盘价计算，合计解禁市值为5.38亿元。从解禁量来看，1家公司解禁股数超千万股。荣旗科技、药康生物、路斯股份解禁量居前，解禁股数分别为1204.46万股、200.0万股、36.9万股。从解禁市值来看，1家公司解禁股数超亿元。荣旗科技、药康生物、路斯股份解禁市值居前，解禁市值分别为5.11亿元、2378.0万元、364.57万元。从解禁股数占总股本比例来看，1家公司解禁比例超10%。荣旗科技、药康生物、路斯股份解禁比例居前，解禁比例分别为22.58%、0.49%、0.36%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404250745147923238c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404250745147923238c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429500631","title":"4月23日药康生物涨5.13%，财通优势行业轮动混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2429500631","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429500631?lang=zh_cn&edition=full","pubTime":"2024-04-23 16:26","pubTimestamp":1713860769,"startTime":"0","endTime":"0","summary":"证券之星消息，4月23日药康生物涨5.13%，收盘报11.88元，换手率2.3%，成交量4.69万手，成交额5475.08万元。重仓药康生物的公募基金请见下表：该股最近90天内共有6家机构给出评级，买入评级4家，增持评级2家；过去90天内机构目标均价为19.37。根据2024基金Q1季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为财通优势行业轮动混合A。该公募基金现任基金经理为张胤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042300029695.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2428553311","title":"药康生物04月18日主力资金流出16万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2428553311","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428553311?lang=zh_cn&edition=full","pubTime":"2024-04-18 15:19","pubTimestamp":1713424760,"startTime":"0","endTime":"0","summary":"04月18日, 药康生物股价跌0.44%，报收11.43元，成交金额3416万元，换手率1.46%，振幅4.09%，量比0.88。药康生物今日主力资金净流出16万元，连续3日净流出，上一交易日主力净流出203万元，今日环比减少92.12%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为66.67%，平均跌幅为2.01%。该股近5个交易日下跌9.00%，主力资金累计净流出480万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入2236万元，其中净流入天数为14日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240418153223878ea70e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240418153223878ea70e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428363032","title":"药康生物大幅上涨 近半年4家券商增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2428363032","media":"智选洞察","top":-1,"share":"https://www.laohu8.com/m/news/2428363032?lang=zh_cn&edition=full","pubTime":"2024-04-17 09:46","pubTimestamp":1713318382,"startTime":"0","endTime":"0","summary":"04月17日，药康生物股价大幅上涨，截至09点46分，药康生物上涨5.06%，报11.63元/股，成交1089万元，换手率0.47%，振幅2.89%。资金动向截止发稿，药康生物获得主力净流出106万元，其中超大单流出61万元，大单流出43万元。北向资金方面，药康生物04月16日获得北向资金增持2.49万股，截至04月16日，北向资金当前共持有药康生物186.76万股，市值2171万元，持股占流通股比为0.92%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404171359157a535ab0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404171359157a535ab0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427841206","title":"药康生物(688046.SH)：200万股限售股4月25日解禁","url":"https://stock-news.laohu8.com/highlight/detail?id=2427841206","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2427841206?lang=zh_cn&edition=full","pubTime":"2024-04-16 18:19","pubTimestamp":1713262784,"startTime":"0","endTime":"0","summary":"格隆汇4月16日丨药康生物(688046.SH)公布，公司本次股票上市流通总数为200万股。股票上市流通日期为2024年4月25日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161819548b2a03dd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161819548b2a03dd&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427184684","title":"4月16日药康生物跌6.27%，财通优势行业轮动混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2427184684","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2427184684?lang=zh_cn&edition=full","pubTime":"2024-04-16 17:33","pubTimestamp":1713260037,"startTime":"0","endTime":"0","summary":"证券之星消息，4月16日药康生物跌6.27%，收盘报11.07元，换手率2.13%，成交量4.35万手，成交额4913.04万元。重仓药康生物的前十大公募基金请见下表：该股最近90天内共有6家机构给出评级，买入评级4家，增持评级2家；过去90天内机构目标均价为19.37。根据2023基金年报公募基金重仓股数据，重仓该股的公募基金共29家，其中持有数量最多的公募基金为财通优势行业轮动混合A。该公募基金现任基金经理为张胤。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161737098b29e21c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161737098b29e21c&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2022-04-25","address":"江苏省南京市浦口区江北新区学府路12号","stockEarnings":[{"period":"1week","weight":0.0707},{"period":"1month","weight":-0.0109},{"period":"3month","weight":0.0016},{"period":"6month","weight":-0.2526},{"period":"1year","weight":-0.4332},{"period":"ytd","weight":-0.3687}],"companyName":"江苏集萃药康生物科技股份有限公司","boardCode":"AI0073","perCapita":"25469股","boardName":"研究和试验发展","registeredCapital":"41000万元","compareEarnings":[{"period":"1week","weight":0.0274},{"period":"1month","weight":0.0209},{"period":"3month","weight":0.1134},{"period":"6month","weight":0.0317},{"period":"1year","weight":-0.0657},{"period":"ytd","weight":0.0437}],"survey":"　　江苏集萃药康生物科技股份有限公司是一家专业从事实验动物小鼠模型的研发、生产、销售及相关技术服务的高新技术企业，主要产品有商品化小鼠模型销售业务、模型定制业务、定制繁育业务、功能药效业务、代理进出口及其他业务。公司为国内模式动物行业龙头企业之一，是亚洲小鼠突变和资源联盟唯一企业成员、国家科技资源共享服务平台（国家遗传工程小鼠资源库）共建单位，先后被认定为国家级高新技术企业、江苏省博士后创新实践基地、江苏省工程技术研究中心、国家级专精特新小巨人企业等。","serverTime":1714651310494,"listedPrice":22.53,"stockholders":"8007人(较上一季度增加26.31%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药康生物(688046)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药康生物(688046)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药康生物,688046,药康生物股票,药康生物股票老虎,药康生物股票老虎国际,药康生物行情,药康生物股票行情,药康生物股价,药康生物股市,药康生物股票价格,药康生物股票交易,药康生物股票购买,药康生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药康生物(688046)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药康生物(688046)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}